CRVO vs. OCS, KRRO, ACIU, CRBP, ANNX, ERAS, VERV, ESPR, LXRX, and TBPH
Should you be buying CervoMed stock or one of its competitors? The main competitors of CervoMed include Oculis (OCS), Korro Bio (KRRO), AC Immune (ACIU), Corbus Pharmaceuticals (CRBP), Annexon (ANNX), Erasca (ERAS), Verve Therapeutics (VERV), Esperion Therapeutics (ESPR), Lexicon Pharmaceuticals (LXRX), and Theravance Biopharma (TBPH). These companies are all part of the "pharmaceutical preparations" industry.
CervoMed (NASDAQ:CRVO) and Oculis (NASDAQ:OCS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, community ranking, institutional ownership, analyst recommendations, risk, profitability and earnings.
25.2% of CervoMed shares are owned by institutional investors. Comparatively, 22.3% of Oculis shares are owned by institutional investors. 2.0% of CervoMed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, Oculis had 4 more articles in the media than CervoMed. MarketBeat recorded 8 mentions for Oculis and 4 mentions for CervoMed. CervoMed's average media sentiment score of 1.05 beat Oculis' score of 0.35 indicating that CervoMed is being referred to more favorably in the media.
CervoMed has higher revenue and earnings than Oculis.
CervoMed currently has a consensus price target of $57.50, suggesting a potential upside of 203.59%. Oculis has a consensus price target of $30.17, suggesting a potential upside of 156.52%. Given CervoMed's higher possible upside, analysts clearly believe CervoMed is more favorable than Oculis.
CervoMed has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500. Comparatively, Oculis has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500.
CervoMed has a net margin of 0.00% compared to Oculis' net margin of -6,712.02%. CervoMed's return on equity of -45.48% beat Oculis' return on equity.
Oculis received 16 more outperform votes than CervoMed when rated by MarketBeat users. However, 100.00% of users gave CervoMed an outperform vote while only 86.36% of users gave Oculis an outperform vote.
Summary
CervoMed beats Oculis on 11 of the 15 factors compared between the two stocks.
Get CervoMed News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRVO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CervoMed Competitors List
Related Companies and Tools
